Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.
Identifieur interne : 000383 ( PubMed/Curation ); précédent : 000382; suivant : 000384Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.
Auteurs : C L Teh ; J S Wong ; H H SooSource :
- Rheumatology international [ 1437-160X ] ; 2012.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antirhumatismaux (usage thérapeutique), Biopsie, Dermatomyosite (diagnostic), Dermatomyosite (traitement médicamenteux), Dermatomyosite (épidémiologie), Facteurs temps, Femelle, Humains, Hydroxychloroquine (usage thérapeutique), Hôpitaux généraux (), Malaisie, Muscles squelettiques (anatomopathologie), Mâle, Polymyosite (diagnostic), Polymyosite (traitement médicamenteux), Polymyosite (épidémiologie), Prednisolone (usage thérapeutique), Prévalence, Sujet âgé, Électromyographie, Études de suivi, Études rétrospectives, Études transversales.
- MESH :
- anatomopathologie : Muscles squelettiques.
- diagnostic : Dermatomyosite, Polymyosite.
- traitement médicamenteux : Dermatomyosite, Polymyosite.
- usage thérapeutique : Antirhumatismaux, Hydroxychloroquine, Prednisolone.
- épidémiologie : Dermatomyosite, Polymyosite.
- Adulte d'âge moyen, Biopsie, Facteurs temps, Femelle, Humains, Hôpitaux généraux, Malaisie, Mâle, Prévalence, Sujet âgé, Électromyographie, Études de suivi, Études rétrospectives, Études transversales.
- Wicri :
- geographic : Malaisie.
English descriptors
- KwdEn :
- Aged, Antirheumatic Agents (therapeutic use), Biopsy, Cross-Sectional Studies, Dermatomyositis (diagnosis), Dermatomyositis (drug therapy), Dermatomyositis (epidemiology), Electromyography, Female, Follow-Up Studies, Hospitals, General (statistics & numerical data), Humans, Hydroxychloroquine (therapeutic use), Malaysia, Male, Middle Aged, Muscle, Skeletal (pathology), Polymyositis (diagnosis), Polymyositis (drug therapy), Polymyositis (epidemiology), Prednisolone (therapeutic use), Prevalence, Retrospective Studies, Time Factors.
- MESH :
- chemical , therapeutic use : Antirheumatic Agents, Hydroxychloroquine, Prednisolone.
- geographic : Malaysia.
- diagnosis : Dermatomyositis, Polymyositis.
- drug therapy : Dermatomyositis, Polymyositis.
- epidemiology : Dermatomyositis, Polymyositis.
- pathology : Muscle, Skeletal.
- statistics & numerical data : Hospitals, General.
- Aged, Biopsy, Cross-Sectional Studies, Electromyography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prevalence, Retrospective Studies, Time Factors.
Abstract
We performed a cross-sectional study of the demography, clinical and laboratory features of patients with polymyositis and dermatomyositis followed up in our centre from 2006 to 2009. There were 12 cases, with the majority of them (58.3%) being woman. They have a mean age of 57.8 years and mean disease duration of 11.83 (SD 9.92) months. Our patients comprised of multi-ethnic groups with predominantly Chinese (83.3%), Sarawak natives (8.3%) and Malays (8.3%). They have a mean lag time to diagnosis of 3.67 (SD 4.27) months. Nine (75%) patients had dermatomyositis and 3(25%) had polymyositis. The common clinical manifestations found in our patients were proximal myopathy (100%), neck weakness (33.3%), dysphagia (33.3%) and interstitial lung disease (33.3%). For the nine patients with dermatomyositis, the most common dermatological manifestations were shawl sign (88.9%) and V sign (88.9%). Muscle enzymes were raised in 91.7% of patients. Electromyographies were carried out in four patients, and only one of our patients had muscle biopsy. Only 41.7% of our patients have positive ANA. The majority received prednisolone (100%) and hydroxychloroquine (58.3%). Malignancy occurred in five (three nasopharyngeal carcinomas, one sigmoid colon cancer and one lung cancer) out of the nine dermatomyositis patients but none in the polymyositis group. The mortality rate in our group was 4(33.3%) over the 4-year period. This study demonstrated the rarity of PM/DM in our centre with considerable lag time to diagnosis in our patients. Despite lack of muscle biopsy in our centre, our centre achieved appropriate diagnosis and management of PM/DM.
DOI: 10.1007/s00296-010-1745-2
PubMed: 21243497
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000383
Links to Exploration step
pubmed:21243497Curation
No country items
C L Teh<affiliation><nlm:affiliation>Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Jalan Hospital, 93450 Kuching, Sarawak, East Malaysia. tehchenglay@yahoo.com</nlm:affiliation><wicri:noCountry code="subField">East Malaysia</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.</title><author><name sortKey="Teh, C L" sort="Teh, C L" uniqKey="Teh C" first="C L" last="Teh">C L Teh</name><affiliation><nlm:affiliation>Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Jalan Hospital, 93450 Kuching, Sarawak, East Malaysia. tehchenglay@yahoo.com</nlm:affiliation><wicri:noCountry code="subField">East Malaysia</wicri:noCountry></affiliation></author><author><name sortKey="Wong, J S" sort="Wong, J S" uniqKey="Wong J" first="J S" last="Wong">J S Wong</name></author><author><name sortKey="Soo, H H" sort="Soo, H H" uniqKey="Soo H" first="H H" last="Soo">H H Soo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:21243497</idno><idno type="pmid">21243497</idno><idno type="doi">10.1007/s00296-010-1745-2</idno><idno type="wicri:Area/PubMed/Corpus">000383</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000383</idno><idno type="wicri:Area/PubMed/Curation">000383</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000383</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.</title><author><name sortKey="Teh, C L" sort="Teh, C L" uniqKey="Teh C" first="C L" last="Teh">C L Teh</name><affiliation><nlm:affiliation>Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Jalan Hospital, 93450 Kuching, Sarawak, East Malaysia. tehchenglay@yahoo.com</nlm:affiliation><wicri:noCountry code="subField">East Malaysia</wicri:noCountry></affiliation></author><author><name sortKey="Wong, J S" sort="Wong, J S" uniqKey="Wong J" first="J S" last="Wong">J S Wong</name></author><author><name sortKey="Soo, H H" sort="Soo, H H" uniqKey="Soo H" first="H H" last="Soo">H H Soo</name></author></analytic><series><title level="j">Rheumatology international</title><idno type="eISSN">1437-160X</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antirheumatic Agents (therapeutic use)</term><term>Biopsy</term><term>Cross-Sectional Studies</term><term>Dermatomyositis (diagnosis)</term><term>Dermatomyositis (drug therapy)</term><term>Dermatomyositis (epidemiology)</term><term>Electromyography</term><term>Female</term><term>Follow-Up Studies</term><term>Hospitals, General (statistics & numerical data)</term><term>Humans</term><term>Hydroxychloroquine (therapeutic use)</term><term>Malaysia</term><term>Male</term><term>Middle Aged</term><term>Muscle, Skeletal (pathology)</term><term>Polymyositis (diagnosis)</term><term>Polymyositis (drug therapy)</term><term>Polymyositis (epidemiology)</term><term>Prednisolone (therapeutic use)</term><term>Prevalence</term><term>Retrospective Studies</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Biopsie</term><term>Dermatomyosite (diagnostic)</term><term>Dermatomyosite (traitement médicamenteux)</term><term>Dermatomyosite (épidémiologie)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Hôpitaux généraux ()</term><term>Malaisie</term><term>Muscles squelettiques (anatomopathologie)</term><term>Mâle</term><term>Polymyosite (diagnostic)</term><term>Polymyosite (traitement médicamenteux)</term><term>Polymyosite (épidémiologie)</term><term>Prednisolone (usage thérapeutique)</term><term>Prévalence</term><term>Sujet âgé</term><term>Électromyographie</term><term>Études de suivi</term><term>Études rétrospectives</term><term>Études transversales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Hydroxychloroquine</term><term>Prednisolone</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Malaysia</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Muscles squelettiques</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dermatomyositis</term><term>Polymyositis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Dermatomyosite</term><term>Polymyosite</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dermatomyositis</term><term>Polymyositis</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dermatomyositis</term><term>Polymyositis</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Muscle, Skeletal</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitals, General</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dermatomyosite</term><term>Polymyosite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term><term>Hydroxychloroquine</term><term>Prednisolone</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Dermatomyosite</term><term>Polymyosite</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Biopsy</term><term>Cross-Sectional Studies</term><term>Electromyography</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Retrospective Studies</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Biopsie</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hôpitaux généraux</term><term>Malaisie</term><term>Mâle</term><term>Prévalence</term><term>Sujet âgé</term><term>Électromyographie</term><term>Études de suivi</term><term>Études rétrospectives</term><term>Études transversales</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Malaisie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed a cross-sectional study of the demography, clinical and laboratory features of patients with polymyositis and dermatomyositis followed up in our centre from 2006 to 2009. There were 12 cases, with the majority of them (58.3%) being woman. They have a mean age of 57.8 years and mean disease duration of 11.83 (SD 9.92) months. Our patients comprised of multi-ethnic groups with predominantly Chinese (83.3%), Sarawak natives (8.3%) and Malays (8.3%). They have a mean lag time to diagnosis of 3.67 (SD 4.27) months. Nine (75%) patients had dermatomyositis and 3(25%) had polymyositis. The common clinical manifestations found in our patients were proximal myopathy (100%), neck weakness (33.3%), dysphagia (33.3%) and interstitial lung disease (33.3%). For the nine patients with dermatomyositis, the most common dermatological manifestations were shawl sign (88.9%) and V sign (88.9%). Muscle enzymes were raised in 91.7% of patients. Electromyographies were carried out in four patients, and only one of our patients had muscle biopsy. Only 41.7% of our patients have positive ANA. The majority received prednisolone (100%) and hydroxychloroquine (58.3%). Malignancy occurred in five (three nasopharyngeal carcinomas, one sigmoid colon cancer and one lung cancer) out of the nine dermatomyositis patients but none in the polymyositis group. The mortality rate in our group was 4(33.3%) over the 4-year period. This study demonstrated the rarity of PM/DM in our centre with considerable lag time to diagnosis in our patients. Despite lack of muscle biopsy in our centre, our centre achieved appropriate diagnosis and management of PM/DM.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21243497</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol. Int.</ISOAbbreviation></Journal><ArticleTitle>Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.</ArticleTitle><Pagination><MedlinePgn>265-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-010-1745-2</ELocationID><Abstract><AbstractText>We performed a cross-sectional study of the demography, clinical and laboratory features of patients with polymyositis and dermatomyositis followed up in our centre from 2006 to 2009. There were 12 cases, with the majority of them (58.3%) being woman. They have a mean age of 57.8 years and mean disease duration of 11.83 (SD 9.92) months. Our patients comprised of multi-ethnic groups with predominantly Chinese (83.3%), Sarawak natives (8.3%) and Malays (8.3%). They have a mean lag time to diagnosis of 3.67 (SD 4.27) months. Nine (75%) patients had dermatomyositis and 3(25%) had polymyositis. The common clinical manifestations found in our patients were proximal myopathy (100%), neck weakness (33.3%), dysphagia (33.3%) and interstitial lung disease (33.3%). For the nine patients with dermatomyositis, the most common dermatological manifestations were shawl sign (88.9%) and V sign (88.9%). Muscle enzymes were raised in 91.7% of patients. Electromyographies were carried out in four patients, and only one of our patients had muscle biopsy. Only 41.7% of our patients have positive ANA. The majority received prednisolone (100%) and hydroxychloroquine (58.3%). Malignancy occurred in five (three nasopharyngeal carcinomas, one sigmoid colon cancer and one lung cancer) out of the nine dermatomyositis patients but none in the polymyositis group. The mortality rate in our group was 4(33.3%) over the 4-year period. This study demonstrated the rarity of PM/DM in our centre with considerable lag time to diagnosis in our patients. Despite lack of muscle biopsy in our centre, our centre achieved appropriate diagnosis and management of PM/DM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teh</LastName><ForeName>C L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Unit of Rheumatology, Department of Medicine, Sarawak General Hospital, Jalan Hospital, 93450 Kuching, Sarawak, East Malaysia. tehchenglay@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Soo</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9PHQ9Y1OLM</RegistryNumber><NameOfSubstance UI="D011239">Prednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003882" MajorTopicYN="N">Dermatomyositis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006769" MajorTopicYN="N">Hospitals, General</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008296" MajorTopicYN="N" Type="Geographic">Malaysia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017285" MajorTopicYN="N">Polymyositis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011239" MajorTopicYN="N">Prednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>08</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21243497</ArticleId><ArticleId IdType="doi">10.1007/s00296-010-1745-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Rheumatol. 1995 Jul;22(7):1300-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7562762</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1975 Feb 13;292(7):344-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1090839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 1993 Dec;52(12):857-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8311535</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Otolaryngol Head Neck Surg. 1995 Nov;121(11):1298-301</Citation><ArticleIdList><ArticleId IdType="pubmed">7576478</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Arthritis Rheum. 1996 Aug;26(1):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">8870112</ArticleId></ArticleIdList></Reference><Reference><Citation>Med J Malaysia. 1995 Mar;50(1):32-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7752973</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Cancer. 2001 Jul 6;85(1):41-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11437400</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Rheumatol. 2006 Mar;25(2):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16477398</ArticleId></ArticleIdList></Reference><Reference><Citation>Australas J Dermatol. 2004 Feb;45(1):77-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14961918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 1990 Oct;17(10):1329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">2254890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2000 Feb;59(2):141-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10666171</ArticleId></ArticleIdList></Reference><Reference><Citation>J Assoc Physicians India. 2002 Oct;50:1255-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12568209</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheum Dis Clin North Am. 2002 Nov;28(4):723-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12510664</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Rheumatol. 2000 Nov;12(6):498-500</Citation><ArticleIdList><ArticleId IdType="pubmed">11092198</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">19499841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000383 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000383 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:21243497
|texte= Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21243497" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |